Fast-expanding Shanghai Pharma breaks ground on $1.8B biotech park focused on next-gen R&D, antibody production
One of China’s biggest biopharma companies is hitting the ground running in 2021.
Shanghai Pharmaceuticals broke ground Monday on a $1.8 billion, 3.2 million-square-foot industrial park dedicated to R&D work in the bustling field of cell and gene therapies as well as manufacturing therapeutic antibodies, the firm said.
The massive site is located in Pudong New Area’s Zhangjiang area and will see construction take place in two phases — 1.08 million square feet for the first, and 2.15 million square feet for the second. News of the groundbreaking and expansion project was first reported by SHINE, a digital news outlet of the Shanghai Daily.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.